{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:17:04Z","timestamp":1782775024690,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"DOI":"10.7759\/cureus.94571","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:04:56Z","timestamp":1760454296000},"source":"Crossref","is-referenced-by-count":2,"title":["Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report"],"prefix":"10.7759","author":[{"given":"Sumeet","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasank","family":"Aramandla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Affan","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thinh  D","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2020.101264","article-title":"Immunology of alopecia areata","volume":"45","author":"\u017beberkiewicz M","year":"2020","unstructured":"\u017beberkiewicz M, Rudnicka L, Malejczyk J. Immunology of alopecia areata. Cent Eur J Immunol. 2020, 45:325-33. 10.5114\/ceji.2020.101264","journal-title":"Cent Eur J Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70182","article-title":"Alopecia areata: pathogenesis, diagnosis, and therapies","volume":"6","author":"Ma T","year":"2025","unstructured":"Ma T, Zhang T, Miao F, et al.. Alopecia areata: pathogenesis, diagnosis, and therapies. MedComm (2020). 2025, 6:e70182. 10.1002\/mco2.70182","journal-title":"MedComm (2020)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052618","article-title":"Immunological properties of atopic dermatitis-associated alopecia areata","volume":"22","author":"Kageyama R","year":"2021","unstructured":"Kageyama R, Ito T, Hanai S, et al.. Immunological properties of atopic dermatitis-associated alopecia areata. Int J Mol Sci. 2021, 22:10.3390\/ijms22052618","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14129","article-title":"Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata","volume":"29","author":"Ito T","year":"2020","unstructured":"Ito T, Kageyama R, Nakazawa S, Honda T. Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata. Exp Dermatol. 2020, 29:726-32. 10.1111\/exd.14129","journal-title":"Exp Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing L","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, et al.. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014, 20:1043-9. 10.1038\/nm.3645","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt CH","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017, 3:17011. 10.1038\/nrdp.2017.11","journal-title":"Nat Rev Dis Primers"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova L","year":"2010","unstructured":"Petukhova L, Duvic M, Hordinsky M, et al.. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010, 466:113-7. 10.1038\/nature09114","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.427","article-title":"Genetic variants in CTLA4 are strongly associated with alopecia areata","volume":"131","author":"John KK","year":"2011","unstructured":"John KK, Brockschmidt FF, Redler S, et al.. Genetic variants in CTLA4 are strongly associated with alopecia areata. J Invest Dermatol. 2011, 131:1169-72. 10.1038\/jid.2010.427","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031038","article-title":"Lifestyle factors involved in the pathogenesis of alopecia areata","volume":"23","author":"Minokawa Y","year":"2022","unstructured":"Minokawa Y, Sawada Y, Nakamura M. Lifestyle factors involved in the pathogenesis of alopecia areata. Int J Mol Sci. 2022, 23:1038. 10.3390\/ijms23031038","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.004","article-title":"The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata","volume":"83","author":"Meah N","year":"2020","unstructured":"Meah N, Wall D, York K, et al.. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020, 83:123-30. 10.1016\/j.jaad.2020.03.004","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.04.012","article-title":"A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men","volume":"57","author":"Olsen EA","year":"2007","unstructured":"Olsen EA, Whiting D, Bergfeld W, et al.. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007, 57:767-74. 10.1016\/j.jaad.2007.04.012","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari A","year":"2018","unstructured":"Jabbari A, Sansaricq F, Cerise J, et al.. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol. 2018, 138:1539-45. 10.1016\/j.jid.2018.01.032","journal-title":"J Invest Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King B","year":"2023","unstructured":"King B, Zhang X, Walter Gubelin Harcha, et al.. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023, 401:1518-29. 10.1016\/s0140-6736(23)00222-2","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the Phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King B","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, et al.. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024, 91:880-8. 10.1016\/j.jaad.2024.06.097","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00711-3","article-title":"Defining severity in alopecia areata: current perspectives and a multidimensional framework","volume":"12","author":"King BA","year":"2022","unstructured":"King BA, Senna MM, Ohyama M, et al.. Defining severity in alopecia areata: current perspectives and a multidimensional framework. Dermatol Ther (Heidelb). 2022, 12:825-34. 10.1007\/s13555-022-00711-3","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cells13070581","article-title":"NF-\u03baB and JAK\/STAT signaling pathways as crucial regulators of neuroinflammation and astrocyte modulation in spinal cord injury","volume":"13","author":"Ageeva T","year":"2024","unstructured":"Ageeva T, Rizvanov A, Mukhamedshina Y. NF-\u03baB and JAK\/STAT signaling pathways as crucial regulators of neuroinflammation and astrocyte modulation in spinal cord injury. Cells. 2024, 13:581. 10.3390\/cells13070581","journal-title":"Cells"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1372810","article-title":"Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis","volume":"15","author":"Yan T","year":"2024","unstructured":"Yan T, Wang T, Tang M, Liu N. Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis. Front Pharmacol. 2024, 15:1372810. 10.3389\/fphar.2024.1372810","journal-title":"Front Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15838","article-title":"Clinical presentations and comorbidities of pediatric alopecia areata","volume":"42 Suppl 1","author":"Mistry J","year":"2025","unstructured":"Mistry J, Sibbald C. Clinical presentations and comorbidities of pediatric alopecia areata. Pediatr Dermatol. 2025, 42 Suppl 1:5-11. 10.1111\/pde.15838","journal-title":"Pediatr Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00240-7","article-title":"\"'You lose your hair, what's the big deal?' I was so embarrassed, I was so self-conscious, I was so depressed:\" a qualitative interview study to understand the psychosocial burden of alopecia areata","volume":"4","author":"Aldhouse NV","year":"2020","unstructured":"Aldhouse NV, Kitchen H, Knight S, et al.. \"'You lose your hair, what's the big deal?' I was so embarrassed, I was so self-conscious, I was so depressed:\" a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020, 4:76. 10.1186\/s41687-020-00240-7","journal-title":"J Patient Rep Outcomes"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004413.pub2","article-title":"Interventions for alopecia areata","author":"Delamere FM","year":"2008","unstructured":"Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008, CD004413. 10.1002\/14651858.CD004413.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","article-title":"Multidiscipline Review: NDA 215830","year":"2023","unstructured":"Multidiscipline Review. NDA 215830. US Food and Drug Administration.  Silver Spring, MD: US Food and Drug Administration, Silver Spring, MD; 2023."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae365","article-title":"Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24\u2005months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata","volume":"192","author":"Piliang M","year":"2025","unstructured":"Piliang M, Soung J, King B, et al.. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24\u2005months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025, 192:215-27. 10.1093\/bjd\/ljae365","journal-title":"Br J Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20526","article-title":"Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study","volume":"39","author":"Tziotzios C","year":"2025","unstructured":"Tziotzios C, Sinclair R, Lesiak A, et al.. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. J Eur Acad Dermatol Venereol. 2025, 39:1152-62. 10.1111\/jdv.20526","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1576553","article-title":"Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis","volume":"16","author":"Qi Z","year":"2025","unstructured":"Qi Z, Li Y. Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis. Front Pharmacol. 2025, 16:1576553. 10.3389\/fphar.2025.1576553","journal-title":"Front Pharmacol"},{"key":"ref25","unstructured":"Leqselvi (deuruxolitinib). (2024). Accessed. September 29, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217900s000lbl.pdf."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.13475","article-title":"Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: a retrospective study","volume":"103","author":"Huang J","year":"2023","unstructured":"Huang J, Deng S, Li J, et al.. Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: a retrospective study. Acta Derm Venereol. 2023, 103:adv13475. 10.2340\/actadv.v103.13475","journal-title":"Acta Derm Venereol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1553904","article-title":"Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report","volume":"16","author":"He Y","year":"2025","unstructured":"He Y, Qi J, Wu Z, Zhang J, Zhang G. Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report. Front Immunol. 2025, 16:1553904. 10.3389\/fimmu.2025.1553904","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King B","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al.. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022, 386:1687-99. 10.1056\/NEJMoa2110343","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/jcia.2024.13890","article-title":"Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study","volume":"7","author":"Uchiyama A","year":"2025","unstructured":"Uchiyama A, Araki T, Kosaka K, Motegi SI. Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study. J Cutan Immunol Allergy. 2025, 7:10.3389\/jcia.2024.13890","journal-title":"J Cutan Immunol Allergy"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.064","article-title":"Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b\/3 trial","volume":"92","author":"Piliang M","year":"2025","unstructured":"Piliang M, Lynde C, King B, et al.. Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b\/3 trial. J Am Acad Dermatol. 2025, 92:276-84. 10.1016\/j.jaad.2024.09.064","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/414272-episodic-neuropathic-like-musculoskeletal-pain-associated-with-ritlecitinib-therapy-in-alopecia-universalis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:05:05Z","timestamp":1760454305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/414272-episodic-neuropathic-like-musculoskeletal-pain-associated-with-ritlecitinib-therapy-in-alopecia-universalis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.94571","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}